Cover Image
市場調查報告書

淋巴球活性化遺傳基因3蛋白:開發中產品分析

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 367843
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
淋巴球活性化遺傳基因3蛋白:開發中產品分析 Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 63 Pages
簡介

本報告提供以淋巴球活性化遺傳基因3蛋白(LAG-3)為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

淋巴球活性化遺傳基因3蛋白(LAG-3) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Crescendo Biologics Ltd
  • Enumeral Biomedical Holdings Inc
  • GlaxoSmithKline Plc
  • Icell Kealex Therapeutics
  • Incyte Corp
  • MacroGenics Inc
  • Merck & Co Inc
  • Novartis AG
  • Prima BioMed Ltd
  • Regeneron Pharmaceuticals Inc
  • Sutro Biopharma Inc
  • Symphogen A/S
  • Tesaro Inc
  • Trellis Bioscience Inc
  • Xencor Inc

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1106TDB

Summary:

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA class-II antigens.

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 22 molecules. Out of which approximately 22 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 8 and 4 respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Advanced Malignancy, Autoimmune Disorders, Lymphoma, Melanoma, Bladder Cancer, Blood Cancer, Cardiovascular Disease, Cervical Cancer, Chronic Inflammation, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Kidney Cancer (Renal Cell Cancer), Non-Hodgkin Lymphoma, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma and Renal Cell Carcinoma.

The latest report Lymphocyte Activation Gene 3 Protein - Pipeline Review, H2 2017, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
  • The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Overview
    • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Companies Involved in Therapeutics Development
    • ARMO Biosciences Inc
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Co
    • Crescendo Biologics Ltd
    • Enumeral Biomedical Holdings Inc
    • GlaxoSmithKline Plc
    • Icell Kealex Therapeutics
    • Incyte Corp
    • MacroGenics Inc
    • Merck & Co Inc
    • Novartis AG
    • Prima BioMed Ltd
    • Regeneron Pharmaceuticals Inc
    • Sutro Biopharma Inc
    • Tesaro Inc
    • Xencor Inc
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Drug Profiles
    • AM-0003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-754111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENUM-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IKT-203 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMP-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMP-731 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMP-761 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LAG-525 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGD-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-4280 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit LAG-3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit LAG3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PD-1 and LAG-3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Target PD-1 and LAG-3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Replace CD223 for Cardiovascular Disease and Chronic Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REGN-2810 + REGN-3767 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REGN-3767 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TSR-033 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XmAb-22841 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Dormant Products
  • Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 08, 2017: Prima Secures Japanese Patent Grant for IMP731 Antibody
      • Sep 05, 2017: MacroGenics Provides Update on its DART candidate MGD013
      • Jul 16, 2017: Prima BioMed Announces Second Milestone Payment for IMP701 Program
      • Jun 03, 2017: Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy
      • May 01, 2017: TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
      • Jan 03, 2017: Prima Announces New Product Candidate IMP761 - A LAG-3 Agonist Antibody
      • Aug 25, 2016: European Patent Grants for IMP731 Antibody
      • Apr 19, 2016: MacroGenics Presents Data from MGD013 Preclinical Program at AACR Annual Meeting 2016
      • Feb 08, 2016: Crescendo Biologics Presents Key Oncology Data on Humabody Drug Conjugates
      • Jan 27, 2016: US Patent Grants for IMP731 Antibody
      • Aug 14, 2015: Prima Biomed Announces Commencement of Milestones for IMP701 Program
      • May 27, 2015: Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by ARMO Biosciences Inc, H2 2017
  • Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Pipeline by Crescendo Biologics Ltd, H2 2017
  • Pipeline by Enumeral Biomedical Holdings Inc, H2 2017
  • Pipeline by GlaxoSmithKline Plc, H2 2017
  • Pipeline by Icell Kealex Therapeutics, H2 2017
  • Pipeline by Incyte Corp, H2 2017
  • Pipeline by MacroGenics Inc, H2 2017
  • Pipeline by Merck & Co Inc, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by Prima BioMed Ltd, H2 2017
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Pipeline by Sutro Biopharma Inc, H2 2017
  • Pipeline by Tesaro Inc, H2 2017
  • Pipeline by Xencor Inc, H2 2017
  • Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top